Hanker et al(Hanker et al. 2017) reported the HER2T798I-mediated neratinib resistance in patients with HER2L869R-mutant BC, and the neratinib resistance could be overcome by other irreversible HER2 inhibitors like afatinib. The gene discussed is ERBB2; the disease is breast cancer.